Rovifarma vaistinė - Company finances
|
EUR
|
2018
From: 2018-01-01
To: 2018-12-31
|
2019
From: 2019-01-01
To: 2019-12-31
|
2020
From: 2020-01-01
To: 2020-12-31
|
2021
From: 2021-01-01
To: 2021-12-31
|
2022
From: 2022-01-01
To: 2022-12-31
|
2023
From: 2023-01-01
To: 2023-12-31
|
2024
From: 2024-01-01
To: 2024-12-31
|
2025
From: 2025-01-01
To: 2025-12-31
|
|---|---|---|---|---|---|---|---|---|
|
Financial data
|
||||||||
| Sales revenue | 4,818,067 | 8,068,223 | 9,625,353 | 12,492,512 | 18,131,694 | 19,501,646 | 22,927,622 | 31,546,115 |
| Profit before tax | 73,425 | 99,006 | 107,542 | 82,463 | 263,402 | 260,960 | 210,490 | 235,605 |
| Net profit | 62,406 | 83,616 | 92,054 | 69,972 | 222,881 | 221,012 | 177,293 | 199,240 |
| Equity | 130,445 | 114,064 | 206,118 | 276,090 | 498,970 | 719,982 | 897,275 | 1,096,515 |
| Liabilities | 1,335,750 | 2,323,013 | 3,255,867 | 3,694,662 | 4,062,989 | 3,676,492 | 4,248,879 | 4,929,312 |
| Non-current assets | 445,013 | 895,318 | 1,039,236 | 1,209,311 | 1,318,816 | 1,182,265 | 1,108,578 | 1,041,320 |
| Current assets | 1,021,182 | 1,536,212 | 2,418,258 | 2,757,132 | 3,238,578 | 3,209,683 | 4,034,933 | 4,983,022 |
| Total assets | 1,466,195 | 2,431,530 | 3,457,494 | 3,966,443 | 4,557,394 | 4,391,948 | 5,143,511 | 6,024,342 |
|
Taxes paid
|
||||||||
| STI taxes | - | - | - | - | - | 129,728 | 109,881 | 101,045 |
| Social insurance contributions | - | - | - | - | - | 37,168 | 38,984 | 58,037 |
|
Financial indicators
|
||||||||
| Revenue change y/y | -13.3% | +67.5% | +19.3% | +29.8% | +45.1% | +7.6% | +17.6% | +37.6% |
| ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. | 4.3% | 3.4% | 2.7% | 1.8% | 4.9% | 5.0% | 3.4% | 3.3% |
| ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. | 47.8% | 73.3% | 44.7% | 25.3% | 44.7% | 30.7% | 19.8% | 18.2% |
| Profit margin Net profit margin. Shows the overall profitability of the company. | 1.3% | 1.0% | 1.0% | 0.6% | 1.2% | 1.1% | 0.8% | 0.6% |
| EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. | 1.5% | 1.2% | 1.1% | 0.7% | 1.5% | 1.3% | 0.9% | 0.7% |
| Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. | 10.2 | 20.4 | 15.8 | 13.4 | 8.1 | 5.1 | 4.7 | 4.5 |
| Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. | 602,258 | 998,135 | 1,203,169 | 1,561,564 | 2,266,462 | 2,437,706 | 2,958,403 | 3,235,499 |
Sales revenue
See Scoris data in Google Search
Mark Scoris as a favorite source. One click, no registration.
Rovifarma vaistinė - Social security debts
| From | To | Debt, € |
|---|---|---|
| 2021-10-18 | 2021-10-19 | 2.75 |
Rovifarma vaistinė - VMI tax arrears
The company had no tax arrears (debts) to the State Tax Inspectorate
VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.
Analysis of the company's financial position
This description was generated by artificial intelligence.
Report if inaccurate.
Rovifarma, UAB (code 141723778) is a Private Limited Liability Company engaged in the retail sale of pharmaceutical products. In 2025, the company generated revenue of €31.55M, up 37.6% year on year and 61.8% over two years, confirming a strong upward sales trajectory from €19.50M in 2023 to €22.93M in 2024 and then to the latest level. Net profit in 2025 was €199.2K, compared with €177.3K in 2024 and €221.0K in 2023, while the profit margin narrowed to 0.6% from 0.8% in 2024 and 1.1% in 2023. Total assets increased to €6.02M in 2025 from €5.14M a year earlier, supported mainly by short-term assets of €4.98M. Equity reached €1.10M, while liabilities rose to €4.93M. The company reported ROE of 18.2%, ROA of 3.3%, a debt-to-equity ratio of 4.50, and asset turnover of 5.24x. Revenue per employee was €3.51M, indicating high operating intensity.